You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Do gliadin and tissue transglutaminase mediate PPAR downregulation in intestinal cells of patients with coeliac disease?
  1. V De Re1,
  2. M P Simula1,
  3. A Notarpietro1,
  4. V Canzonieri2,
  5. R Cannizzaro3,
  6. G Toffoli1
  1. 1Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico, IRCCS, National Cancer Insitute, Aviano, Pordenone, Italy
  2. 2Pathology, Centro di Riferimento Oncologico, IRCCS, National Cancer Insitute, Aviano, Pordenone, Italy
  3. 3Gastroenterology, Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano, Pordenone, Italy
  1. Correspondence to Dr Valli De Re, Experimental and Clinical Pharmacology, Department of Molecular Oncology and Translational Medicine (DOMERT), Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Via F. Gallini, 2, 33081 Aviano, Italy; vdere{at}cro.it

https://doi.org/10.1136/gut.2010.209395

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The accumulation of toxic gliadin peptide was proposed to initiate tissue transglutaminase (tTG) upregulation in coeliac intestine.1 Upregulation of tTG drives inflammation through the ubiquitination and proteasomal degradation of the anti-inflammatory peroxisome proliferator-activated receptor (PPAR). To understand further the contribution to mucosal-associated damage in coeliac disease caused by tTG upregulation, we have quantified the expression levels of several proteins directly involved in the PPAR signalling pathway and/or related to PPAR activation. Our study population consisted of patients with coeliac disease at first diagnosis with gut inflammation (n=1 Marsh 2; n=5 Marsh 3; immunoglobulin A (IgA)-tTG ≥cut-off); IgA-tTG-negative patients with coeliac disease who had recovered from intestinal damage while on a gluten-free diet (GFD) (n=4 Marsh 0–1); and control patients with excluded …

    View Full Text

    Footnotes

    • Funding Programma Integrato Oncologia, Tematica 2 and Associazione Italiana Celiachia (AIC).

    • Competing interests None.

    • Ethics approval This study was conducted with the approval of the ethics committee inAviano, Italy.

    • Provenance and peer review Not commissioned; not externally peer reviewed.